Please enable JavaScript to continue using this application.

Compare tickers

Valuation, margins, and growth side by side.

Compare $PTGX vs $TGTX | Chartloom

Compare

$PTGX vs $TGTX

Protagonist Therapeutics Inc · TG Therapeutics Inc

PTGX

Protagonist Therapeutics Inc

TGTX

TG Therapeutics Inc

Compare $PTGX vs $TGTX

Comparing Protagonist Therapeutics Inc and TG Therapeutics Inc

PTGXProtagonist Therapeutics Inc

TGTXTG Therapeutics Inc

PTGXProtagonist Therapeutics Inc

Market cap

$8.91B

P/E (TTM)

118.61x

Forward P/E (NTM)

74.88x

Forward P/S (NTM)

22.88x

Rev growth (TTM)

34.8%

YTD performance

58.9%

52W performance

59.2%

FCF yield

1.5%

TGTXTG Therapeutics Inc

Market cap

$8.32B

P/E (TTM)

19.36x

Forward P/E (NTM)

27.77x

Forward P/S (NTM)

7.37x

Rev growth (TTM)

76.1%

YTD performance

85.6%

52W performance

61.0%

FCF yield

0.2%

Add ticker

Add up to 1 more ticker to compare

Relative performance

Each ticker starts at 100. 110 means +10% from the start of this window — not a $110 share price.

PTGX

TGTX

Detailed metrics comparison

PTGX

Protagonist Therapeutics Inc

TGTX

TG Therapeutics Inc

Market Cap

PTGX$8.91B

TGTX$8.32B

Enterprise Value

PTGX$8.49B

TGTX$8.58B

Price

PTGX$138.49

TGTX$54.34

P/E Ratio

PTGX118.61x

TGTX19.36x

P/S Ratio

PTGX31.58x

TGTX10.40x

EV/Sales

PTGX30.09x

TGTX10.73x

EV/EBITDA

PTGX134.54x

TGTX61.91x

P/B Ratio

PTGX11.05x

TGTX14.03x

P/FCF Ratio

PTGX68.20x

TGTX478.48x

EV/FCF

PTGX64.99x

TGTX493.60x

PEG Ratio

PTGX2.96x

TGTX0.83x

Forward P/E (NTM)

PTGX74.88x

TGTX27.77x

Forward P/S (NTM)

PTGX22.88x

TGTX7.37x

Revenue (TTM)

PTGX$282M

TGTX$800M

Revenue Growth (YoY)

PTGX34.8%

TGTX76.1%

Forward Rev Growth

PTGX-70.6%

TGTX35.6%

Gross Margin (TTM)

PTGX0.0%

TGTX82.4%

Operating Margin (TTM)

PTGX20.7%

TGTX15.9%

EBITDA Margin (TTM)

PTGX21.2%

TGTX17.1%

Net Margin (TTM)

PTGX29.4%

TGTX55.2%

FCF Margin (TTM)

PTGX46.3%

TGTX2.2%

Net Income (TTM)

PTGX$83M

TGTX$441M

FCF (TTM)

PTGX$131M

TGTX$17M

EPS (TTM)

PTGX$1.17

TGTX$2.81

ROE (TTM)

PTGX12.0%

TGTX72.3%

ROA (TTM)

PTGX11.2%

TGTX33.6%

ROIC (TTM)

PTGX12.0%

TGTX39.9%

Cash

PTGX$420M

TGTX$483M

Debt

PTGX$0

TGTX$745M

Net Cash/Debt

PTGX$420M

TGTX$-263M

Current Ratio (TTM)

PTGX21.71x

TGTX4.27x

Quick Ratio (TTM)

PTGX21.58x

TGTX3.72x

Debt/Equity (TTM)

PTGX0.00x

TGTX1.23x

Debt/Assets (TTM)

PTGX0.0%

TGTX0.0%

Interest Coverage (TTM)

PTGXN/A

TGTXN/A

Net Debt/EBITDA (TTM)

PTGX0.00x

TGTX0.00x

Beta

PTGX1.19

TGTX1.82

52W Performance

PTGX59.2%

TGTX61.0%

YTD Performance

PTGX58.9%

TGTX85.6%

% from 52W High

PTGX-13.9%

TGTX-8.4%

% from 52W Low

PTGX89.5%

TGTX103.1%

Asset Turnover (TTM)

PTGX0.38x

TGTX0.61x

FCF Yield (TTM)

PTGX1.5%

TGTX0.2%

Earnings Yield (TTM)

PTGX0.9%

TGTX5.3%

Dividend Yield (TTM)

PTGXN/A

TGTXN/A

Rule of 40

PTGX81.1

TGTX78.3

EV/GP/RG

PTGXN/A

TGTX0.31

Ticker research

View PTGX research View TGTX research

Metric	PTGX Protagonist Therapeutics Inc	TGTX TG Therapeutics Inc
Market & Valuation
Market Cap	$8.91B	$8.32B
Enterprise Value	$8.49B	$8.58B
Price	$138.49	$54.34
P/E Ratio	118.61x	19.36x
P/S Ratio	31.58x	10.40x
EV/Sales	30.09x	10.73x
EV/EBITDA	134.54x	61.91x
P/B Ratio	11.05x	14.03x
P/FCF Ratio	68.20x	478.48x
EV/FCF	64.99x	493.60x
PEG Ratio	2.96x	0.83x
Forward P/E (NTM)	74.88x	27.77x
Forward P/S (NTM)	22.88x	7.37x
Revenue & Growth
Revenue (TTM)	$282M	$800M
Revenue Growth (YoY)	34.8%	76.1%
Forward Rev Growth	-70.6%	35.6%
Profitability
Gross Margin (TTM)	0.0%	82.4%
Operating Margin (TTM)	20.7%	15.9%
EBITDA Margin (TTM)	21.2%	17.1%
Net Margin (TTM)	29.4%	55.2%
FCF Margin (TTM)	46.3%	2.2%
Net Income (TTM)	$83M	$441M
FCF (TTM)	$131M	$17M
EPS (TTM)	$1.17	$2.81
ROE (TTM)	12.0%	72.3%
ROA (TTM)	11.2%	33.6%
ROIC (TTM)	12.0%	39.9%
Financial Health
Cash	$420M	$483M
Debt	$0	$745M
Net Cash/Debt	$420M	$-263M
Current Ratio (TTM)	21.71x	4.27x
Quick Ratio (TTM)	21.58x	3.72x
Debt/Equity (TTM)	0.00x	1.23x
Debt/Assets (TTM)	0.0%	0.0%
Interest Coverage (TTM)	N/A	N/A
Net Debt/EBITDA (TTM)	0.00x	0.00x
Performance
Beta	1.19	1.82
52W Performance	59.2%	61.0%
YTD Performance	58.9%	85.6%
% from 52W High	-13.9%	-8.4%
% from 52W Low	89.5%	103.1%
Efficiency & Yields
Asset Turnover (TTM)	0.38x	0.61x
FCF Yield (TTM)	1.5%	0.2%
Earnings Yield (TTM)	0.9%	5.3%
Dividend Yield (TTM)	N/A	N/A
Other
Rule of 40	81.1	78.3
EV/GP/RG	N/A	0.31
Ticker research	View PTGX research	View TGTX research

Valuation

P/E Ratio

TGTX

19.36x

PTGX

118.61x

P/S Ratio

TGTX

10.40x

PTGX

31.58x

EV/FCF

PTGX

64.99x

TGTX

493.60x

Growth & revenue

Revenue Growth TTM

TGTX

76.1%

PTGX

34.8%

Forward Revenue Growth

TGTX

35.6%

PTGX

-70.6%

Profitability & performance

Gross Margin

TGTX

82.4%

PTGX

0.0%

ROE

TGTX

72.3%

PTGX

12.0%

FCF Yield %

PTGX

1.5%

TGTX

0.2%

52-Week Performance

TGTX

61.0%

PTGX

59.2%

Detailed metrics comparison

PTGX

Protagonist Therapeutics Inc

TGTX

TG Therapeutics Inc

Market Cap

PTGX$8.91B

TGTX$8.32B

Enterprise Value

PTGX$8.49B

TGTX$8.58B

Price

PTGX$138.49

TGTX$54.34

P/E Ratio

PTGX118.61x

TGTX19.36x

P/S Ratio

PTGX31.58x

TGTX10.40x

EV/Sales

PTGX30.09x

TGTX10.73x

EV/EBITDA

PTGX134.54x

TGTX61.91x

P/B Ratio

PTGX11.05x

TGTX14.03x

P/FCF Ratio

PTGX68.20x

TGTX478.48x

EV/FCF

PTGX64.99x

TGTX493.60x

PEG Ratio

PTGX2.96x

TGTX0.83x

Forward P/E (NTM)

PTGX74.88x

TGTX27.77x

Forward P/S (NTM)

PTGX22.88x

TGTX7.37x

Revenue (TTM)

PTGX$282M

TGTX$800M

Revenue Growth (YoY)

PTGX34.8%

TGTX76.1%

Forward Rev Growth

PTGX-70.6%

TGTX35.6%

Gross Margin (TTM)

PTGX0.0%

TGTX82.4%

Operating Margin (TTM)

PTGX20.7%

TGTX15.9%

EBITDA Margin (TTM)

PTGX21.2%

TGTX17.1%

Net Margin (TTM)

PTGX29.4%

TGTX55.2%

FCF Margin (TTM)

PTGX46.3%

TGTX2.2%

Net Income (TTM)

PTGX$83M

TGTX$441M

FCF (TTM)

PTGX$131M

TGTX$17M

EPS (TTM)

PTGX$1.17

TGTX$2.81

ROE (TTM)

PTGX12.0%

TGTX72.3%

ROA (TTM)

PTGX11.2%

TGTX33.6%

ROIC (TTM)

PTGX12.0%

TGTX39.9%

Cash

PTGX$420M

TGTX$483M

Debt

PTGX$0

TGTX$745M

Net Cash/Debt

PTGX$420M

TGTX$-263M

Current Ratio (TTM)

PTGX21.71x

TGTX4.27x

Quick Ratio (TTM)

PTGX21.58x

TGTX3.72x

Debt/Equity (TTM)

PTGX0.00x

TGTX1.23x

Debt/Assets (TTM)

PTGX0.0%

TGTX0.0%

Interest Coverage (TTM)

PTGXN/A

TGTXN/A

Net Debt/EBITDA (TTM)

PTGX0.00x

TGTX0.00x

Beta

PTGX1.19

TGTX1.82

52W Performance

PTGX59.2%

TGTX61.0%

YTD Performance

PTGX58.9%

TGTX85.6%

% from 52W High

PTGX-13.9%

TGTX-8.4%

% from 52W Low

PTGX89.5%

TGTX103.1%

Asset Turnover (TTM)

PTGX0.38x

TGTX0.61x

FCF Yield (TTM)

PTGX1.5%

TGTX0.2%

Earnings Yield (TTM)

PTGX0.9%

TGTX5.3%

Dividend Yield (TTM)

PTGXN/A

TGTXN/A

Rule of 40

PTGX81.1

TGTX78.3

EV/GP/RG

PTGXN/A

TGTX0.31

Ticker research

View PTGX research View TGTX research

Metric	PTGX Protagonist Therapeutics Inc	TGTX TG Therapeutics Inc
Market & Valuation
Market Cap	$8.91B	$8.32B
Enterprise Value	$8.49B	$8.58B
Price	$138.49	$54.34
P/E Ratio	118.61x	19.36x
P/S Ratio	31.58x	10.40x
EV/Sales	30.09x	10.73x
EV/EBITDA	134.54x	61.91x
P/B Ratio	11.05x	14.03x
P/FCF Ratio	68.20x	478.48x
EV/FCF	64.99x	493.60x
PEG Ratio	2.96x	0.83x
Forward P/E (NTM)	74.88x	27.77x
Forward P/S (NTM)	22.88x	7.37x
Revenue & Growth
Revenue (TTM)	$282M	$800M
Revenue Growth (YoY)	34.8%	76.1%
Forward Rev Growth	-70.6%	35.6%
Profitability
Gross Margin (TTM)	0.0%	82.4%
Operating Margin (TTM)	20.7%	15.9%
EBITDA Margin (TTM)	21.2%	17.1%
Net Margin (TTM)	29.4%	55.2%
FCF Margin (TTM)	46.3%	2.2%
Net Income (TTM)	$83M	$441M
FCF (TTM)	$131M	$17M
EPS (TTM)	$1.17	$2.81
ROE (TTM)	12.0%	72.3%
ROA (TTM)	11.2%	33.6%
ROIC (TTM)	12.0%	39.9%
Financial Health
Cash	$420M	$483M
Debt	$0	$745M
Net Cash/Debt	$420M	$-263M
Current Ratio (TTM)	21.71x	4.27x
Quick Ratio (TTM)	21.58x	3.72x
Debt/Equity (TTM)	0.00x	1.23x
Debt/Assets (TTM)	0.0%	0.0%
Interest Coverage (TTM)	N/A	N/A
Net Debt/EBITDA (TTM)	0.00x	0.00x
Performance
Beta	1.19	1.82
52W Performance	59.2%	61.0%
YTD Performance	58.9%	85.6%
% from 52W High	-13.9%	-8.4%
% from 52W Low	89.5%	103.1%
Efficiency & Yields
Asset Turnover (TTM)	0.38x	0.61x
FCF Yield (TTM)	1.5%	0.2%
Earnings Yield (TTM)	0.9%	5.3%
Dividend Yield (TTM)	N/A	N/A
Other
Rule of 40	81.1	78.3
EV/GP/RG	N/A	0.31
Ticker research	View PTGX research	View TGTX research